



## Reslizumab

Revised: December 3, 2018.

CASRN: 241473-69-8

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of reslizumab during breastfeeding. Because reslizumab is a large protein molecule with a molecular weight of 147,000, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant's gastrointestinal tract. Until more data become available, reslizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Reslizumab

### CAS Registry Number

241473-69-8

## Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized